Ai Technology Group INC. 8-K Filing
Ticker: AIPG · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1289047
| Field | Detail |
|---|---|
| Company | Ai Technology Group INC. (AIPG) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1,125,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ai Technology Group INC. (ticker: AIPG) to the SEC on Dec 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $1,125,000 (tanding convertible debentures totaling $1,125,000, convertible into 584,800 common shares).
How long is this filing?
Ai Technology Group INC.'s 8-K filing is 2 pages with approximately 595 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-12-17 15:56:28
Key Financial Figures
- $1,125,000 — tanding convertible debentures totaling $1,125,000, convertible into 584,800 common shares
Filing Documents
- aipg_8k.htm (8-K) — 22KB
- aipg_ex21.htm (EX-2.1) — 55KB
- 0001477932-25-009007.txt ( ) — 191KB
- aipg-20251217.xsd (EX-101.SCH) — 5KB
- aipg-20251217_lab.xml (EX-101.LAB) — 13KB
- aipg-20251217_cal.xml (EX-101.CAL) — 1KB
- aipg-20251217_pre.xml (EX-101.PRE) — 8KB
- aipg-20251217_def.xml (EX-101.DEF) — 2KB
- aipg_8k_htm.xml (XML) — 3KB
01 – Entry into a Material Definitive Agreement
Item 1.01 – Entry into a Material Definitive Agreement On December 15, 2025, AI Technology Group Inc. (the "Corporation") entered into a Share Exchange Agreement with AVM Biotechnology Inc. , a Nevada corporation ("AVM"), and Biomed 360 Solutions Corp. , a British Columbia corporation ("Biomed 360"), the sole shareholder of AVM. Under the terms of the agreement, the Corporation agreed to acquire 100% of the issued and outstanding shares of AVM in exchange for 100 common shares of the Corporation . As a result, AVM became a wholly-owned subsidiary of the Corporation. The transaction is intended to qualify as a tax-free reorganization under Section 368 of the Internal Revenue Code of 1986, as amended.
01 – Completion of Acquisition or Disposition of Assets
Item 2.01 – Completion of Acquisition or Disposition of Assets On December 15, 2025, the Corporation completed the acquisition of AVM. Consideration: 100 common shares of the Corporation issued to Biomed 360 in exchange for 100 common shares of AVM. Result: AVM is now a wholly-owned subsidiary of the Corporation. Convertible Debentures: AVM has outstanding convertible debentures totaling $1,125,000, convertible into 584,800 common shares of the Corporation. These debentures will be converted into common shares of the Corporation pursuant to the agreement.
02 – Unregistered Sales of Equity Securities
Item 3.02 – Unregistered Sales of Equity Securities The shares issued in connection with the acquisition were not registered under the Securities Act of 1933 and are considered restricted securities under Rule 144. The issuance was made in reliance upon exemptions from registration provided by Section 4(a)(2) of the Securities Act.
01 – Financial Statements and Exhibits
Item 9.01 – Financial Statements and Exhibits Exhibit 2.1 Share Exchange Agreement dated December 15, 2025, among AI Technology Group Inc., AVM Biotechnology Inc., and Biomed 360 Solutions Corp. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AI TECHNOLOGY GROUP INC. Date: December 17, 2025 By: /s/ Marcus Johnson Marcus Johnson Chief Executive Officer 3